Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 60.14% is in line with its 5-year average of 62.80%, near the high end of its 5-year range (25.63%–68.05%).
1.21% below its 12-month average of 60.88%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 62.30%.
GROSS MARGIN
60.14%
GROSS MARGIN AVG TTM
60.88%
GROSS MARGIN AVG 3Y
63.38%
GROSS MARGIN AVG 5Y
62.80%
GROSS MARGIN AVG 10Y
52.97%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.21%
CURRENT VS 3Y AVG
-5.12%
CURRENT VS 5Y AVG
-4.24%
CURRENT VS 10Y AVG
+13.53%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.32%
median of 777 covered companies
CURRENT VS SECTOR MEDIAN
+49.16%
vs the sector median at left
Lantheus Holdings, Inc.
Market Cap
$6.50B
Gross Margin
60.14%
TTM Avg
60.88%
3Y Avg
63.38%
5Y Avg
62.80%
Market Cap
$6.49B
Gross Margin
39.32%
TTM Avg
37.08%
3Y Avg
36.51%
5Y Avg
35.71%
Market Cap
$6.57B
Gross Margin
73.84%
TTM Avg
76.65%
3Y Avg
78.21%
5Y Avg
76.94%
Market Cap
$6.25B
Gross Margin
89.00%
TTM Avg
89.73%
3Y Avg
89.61%
5Y Avg
73.24%
Market Cap
$5.94B
Gross Margin
98.58%
TTM Avg
95.46%
3Y Avg
84.33%
5Y Avg
82.16%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | $6.50B | 60.14% | 60.88% | 63.38% | 62.80% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.49B | 39.32% | 37.08% | 36.51% | 35.71% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.57B | 73.84% | 76.65% | 78.21% | 76.94% |
| Immunovant, Inc. (IMVT)vs › | $6.55B | 0.00% | 0.00% | 0.00% | 0.00% |
| Chemed Corporation (CHE)vs › | $6.66B | 30.44% | 32.55% | 34.06% | 34.32% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.25B | 89.00% | 89.73% | 89.61% | 73.24% |
| GRAIL Inc. (GRAL)vs › | $6.02B | -42.52% | -52.32% | -104.24% | -183.56% |
| Alkermes plc (ALKS)vs › | $7.00B | 84.56% | 85.47% | 84.03% | 83.69% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.94B | 98.58% | 95.46% | 84.33% | 82.16% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.91B | 97.23% | 60.83% | -170.72% | -113.81% |
Gross Margin
60.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 62.30% |
| 2026-03-31 | 61.20% |
| 2025-12-31 | 59.21% |
| 2025-09-30 | 57.91% |
| 2025-06-30 | 63.75% |
| 2025-03-31 | 63.77% |
| 2024-12-31 | 63.55% |
| 2024-09-30 | 63.93% |
| 2024-06-30 | 64.90% |
| 2024-03-31 | 68.05% |
| 2023-12-31 | 64.93% |
| 2023-09-30 | 62.50% |
| 2023-06-30 | 62.99% |
| 2023-03-31 | 25.63% |
| 2022-12-31 | 63.52% |
| 2022-09-30 | 61.61% |
| 2022-06-30 | 61.70% |
| 2022-03-31 | 61.79% |
| 2021-12-31 | 44.70% |
| 2021-09-30 | 41.80% |
| 2021-06-30 | 45.60% |
| 2021-03-31 | 44.35% |
| 2020-12-31 | 41.05% |
| 2020-09-30 | 40.95% |
| 2020-06-30 | 39.16% |
| 2020-03-31 | 41.90% |
| 2019-12-31 | 49.88% |
| 2019-09-30 | 48.49% |
| 2019-06-30 | 52.01% |
| 2019-03-31 | 50.96% |
| 2018-12-31 | 50.82% |
| 2018-09-30 | 50.49% |
| 2018-06-30 | 51.24% |
| 2018-03-31 | 51.20% |
| 2017-12-31 | 46.65% |
| 2017-09-30 | 48.19% |
| 2017-06-30 | 51.72% |
| 2017-03-31 | 48.87% |
| 2016-12-31 | 46.60% |
| 2016-09-30 | 46.10% |
| 2016-06-30 | 45.85% |
| 2016-03-31 | 44.07% |
| 2015-12-31 | 46.88% |
| 2015-09-30 | 45.47% |
| 2015-06-30 | 44.56% |
| 2015-03-31 | 47.80% |
| 2014-12-31 | 42.56% |
| 2014-09-30 | 41.80% |
| 2014-06-30 | 41.08% |
| 2014-03-31 | 40.99% |
| 2013-12-31 | 13.79% |
| 2013-09-30 | 33.70% |
| 2013-06-30 | 29.67% |
| 2013-03-31 | 32.12% |
| 2012-12-31 | 38.03% |
